Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2000
11/23/2000WO2000069255A1 Anti-inflammatory therapy for inflammatory mediated infection
11/23/2000WO2000043371A3 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
11/23/2000WO2000043354A3 Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
11/23/2000WO2000041540A3 Herbal supplement for increased muscle strength and endurance for athletes
11/23/2000WO2000040589A3 Novel derivatives from the class of oleandomycin
11/23/2000WO2000040232A3 Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
11/23/2000WO2000038706A3 Methods for treating cancer and for mediating chemotaxis of dendritic cells
11/23/2000WO2000038690A3 Prostaglandin e agonists for treatment of dry eye
11/23/2000WO2000037685A9 Method of identifying a psychotropic agent using differential gene expression
11/23/2000WO2000037067A9 Sensitizing agents for the treatment of skin lesions
11/23/2000WO2000036918A9 Methods and compositions for treatment of cell proliferative disorders
11/23/2000WO2000035920A3 4,5-azolo-oxindoles
11/23/2000WO2000034295A3 Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
11/23/2000WO2000034237A3 Acetamide and substituted acetamide-containing thiourea inhibitors of herpes viruses
11/23/2000WO2000033812A3 Transdermal patch for delivering volatile liquid drugs
11/23/2000WO2000032267A3 Device for locally delivering a drug in a body cavity
11/23/2000WO2000032221A3 Promotion or inhibition of angiogenesis and cardiovascularization
11/23/2000WO2000031100A3 Benzylmaltosides as inhibitors of smooth muscle cell proliferation
11/23/2000WO2000030627A3 Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
11/23/2000WO2000030626A3 Methods and kits for treating vulvovaginal candidiasis with miconazole nitrate
11/23/2000WO2000029556A3 Identification of glycosphingolipids that promote hiv-1 entry into cells
11/23/2000WO2000028020A3 Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
11/23/2000WO2000027423A3 Methods and compositions for treating common cold symptoms
11/23/2000WO2000027381A3 Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions
11/23/2000WO2000027194A9 Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
11/23/2000WO2000023100A3 Genes and proteins predictive and therapeutic for renal disease and associated disorders
11/23/2000WO2000023059A3 Use of anticonvulsant derivatives for treating alcohol dependency
11/23/2000WO2000021486A9 Prevention of uv-induced functional vitamin a deficiency through use of topically applied retinoid
11/23/2000WO2000020450A3 Calcium channel alpha-2/delta gene
11/23/2000WO2000019978A3 Compositions and methods for enhancing receptor-mediated cellular internalization
11/23/2000WO2000016764A3 Pharmaceutical compositions comprising derivatives of sulphur acids
11/23/2000WO2000015790A3 Leptin induced genes
11/23/2000WO2000015666A3 Compositions and methods for the treatment of tumors
11/23/2000WO2000013681A3 4-quinolinemethanol derivatives as purine receptor antagonists (i)
11/23/2000WO2000010552A3 Use of anti-angiogenic agents for inhibiting vessel wall injury
11/23/2000WO2000009111A3 Inhibitors of amyloid formation
11/23/2000WO1999065871A3 Thiolesters and uses thereof
11/23/2000WO1999061398A3 24-hydroxyvitamin d, analogs and uses thereof
11/23/2000WO1999048482A3 Smilagenin and anzurogenin-d for the treatment of alzheimer's disease
11/23/2000WO1999004775A3 Method of treating dopaminergic and gaba-nergic disorders
11/23/2000DE19923829A1 Complex of hyaluronate, active ingredient and water, useful as topical pharmaceutical or cosmetic composition, is stable and has high content of active agent
11/23/2000DE19923427A1 Device for improved delivery of active agents to skin, useful e.g. for administering opiates, contains agent that increases local skin temperature or blood flow
11/23/2000DE19923086A1 New cinnamoylaminoalkyl-substituted benzenesulfonamide derivatives, are ATP-sensitive potassium channel inhibitors and vagal nervous system stimulants useful for treating cardiovascular disorders
11/23/2000DE19922462A1 New phenylureidobenzyl-substituted spiro-imidazolidinedione derivatives, are inhibitors of leukocyte adhesion or migration or VLA-4 receptors, useful e.g. for treating inflammatory or allergic disease
11/23/2000DE19921794A1 Neue pharmazeutische Zusammensetzung New pharmaceutical composition
11/23/2000CA2376722A1 Chloramphenicol biosynthetic pathway and gene cluster characterization
11/23/2000CA2375219A1 Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
11/23/2000CA2374559A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
11/23/2000CA2374297A1 Furanone derivatives as inhibitors of cathepsin s
11/23/2000CA2374235A1 Production of complex carbohydrates
11/23/2000CA2374108A1 Anionic polymers as toxin binders and antibacterial agents
11/23/2000CA2374085A1 Tumour treatment with anti-erbb2 antibodies
11/23/2000CA2373975A1 Glycosaminoglycans having an average molecular weight equal to 2400 d suitable for the treatment of senile dementia
11/23/2000CA2373942A1 Remedies or prophylactis for diseases in association with chemokines
11/23/2000CA2373931A1 Dfmo and celecoxib in combination for cancer chemoprevention and therapy
11/23/2000CA2373892A1 Glucagon antagonists/inverse agonists
11/23/2000CA2373855A1 Method of treating psychotic disorders
11/23/2000CA2373697A1 Method of inhibiting neurotrophin-receptor binding
11/23/2000CA2373681A1 Pharmaceutical compositions for treating angina and/or anginal equivalents, and kit relating thereto
11/23/2000CA2373666A1 Benzofuranylsulfonates
11/23/2000CA2373629A1 Transdermal therapeutic system (tts) containing tolterodine
11/23/2000CA2373614A1 Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants
11/23/2000CA2373610A1 Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
11/23/2000CA2373607A1 Cyclic amine derivatives and their uses
11/23/2000CA2373603A1 Novel diphenylethylene compounds
11/23/2000CA2373532A1 Morpholino-n-ethyl ester derivative of an indole spla2 inhibitor
11/23/2000CA2373509A1 Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
11/23/2000CA2373500A1 Hydroxamic acid derivatives as matrix metalloprotease inhibitors
11/23/2000CA2373439A1 Novel hydroxamic acid derivatives
11/23/2000CA2373416A1 Method of inhibiting neurotrophin-receptor binding
11/23/2000CA2373194A1 Methods of regulating the condition of mammalian keratinous tissue
11/23/2000CA2373191A1 Full-length molecules expressed in human tissues
11/23/2000CA2373158A1 Methods for regulating the condition of mammalian keratinous tissue via topical application of phytosterol compositions
11/23/2000CA2372934A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
11/23/2000CA2372926A1 143 human secreted proteins
11/23/2000CA2372919A1 Remote and local controlled delivery of pharmaceutical compounds using electromagnetic energy
11/23/2000CA2372783A1 Identifying material from a breast duct
11/23/2000CA2372617A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
11/23/2000CA2372549A1 Ox2 receptor homologs
11/23/2000CA2372541A1 Sphingosine kinase enzyme
11/23/2000CA2372494A1 Compounds having cytokine inhibitory activity
11/23/2000CA2372429A1 4,5,6,7-tetrahydroindazole derivatives as antitumor agents
11/23/2000CA2372426A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/23/2000CA2372119A1 Neuroprotective properties of gdf-15, a novel member of the tgf-.beta. superfamily
11/23/2000CA2372068A1 Sulphostin analogue and process for producing sulphostin and its analogue
11/23/2000CA2372051A1 Imidazo-containing heterocyclic compounds, their compositions and uses
11/23/2000CA2372044A1 Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
11/23/2000CA2372032A1 Compounds and therapeutic methods
11/23/2000CA2371551A1 Pharmaceutical compositions comprising apocodeine and/or its derivatives
11/23/2000CA2371212A1 Differential gene expression in specific regions of the brain in neurodegenerative diseases
11/23/2000CA2370786A1 Antiperspirant and deodorant compositions containing cyclohexasiloxane
11/23/2000CA2370245A1 Enzyme-activated anti-tumor prodrug compounds
11/23/2000CA2370066A1 Thiazolopyrimidines useful as tnf.alpha. inhibitors
11/23/2000CA2369376A1 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer and for prevention of cancer in at-risk subjects
11/23/2000CA2369369A1 Buforin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins
11/23/2000CA2368833A1 Molecules expressed in hippocampus
11/23/2000CA2368640A1 A composition containing carvacrol and thymol for use as a bactericide
11/23/2000CA2368620A1 Genetic modification of male germ cells for generation of transgenic species and genetic therapies
11/23/2000CA2368593A1 Anti-inflammatory therapy for inflammatory mediated infection
11/22/2000EP1054058A1 Pharmaceutical composition for treatment of Duchenne muscular dystrophy
1 ... 6204 6205 6206 6207 6208 6209 6210 6211 6212 6213 6214 6215 6216 6217 6218 6219 6220 6221 6222 6223 6224 ... 7860